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Abstract:  Minocycline, a tetracycline antibiotic, is now known to protect cells via an anti-inflammatory mechanism. We 
further explored this effect using an in vitro model of ischemia-like injury to neurons. Coculturing neurons with microglia, 
the brain’s resident immune cell, modestly increased cell death due to oxygen and glucose deprivation (OGD), compared to 
neurons alone.  Treatment of cocultures with minocycline decreased cell death to a level significantly lower than that of neurons 
alone.  Treatment of cocultures with minocycline or inhibitors of various immune mediators, also led to decreased cell death. 
Importantly, treatment of neuron cultures without added microglia  with these same inhibitors of tissue plasminogen activator, 
matrix metalloproteinases, TNF-alpha and inducible nitric oxide synthase  as well as minocycline also led to decreased cell 
death. Thus, anti-inflammatory treatments appear to be directly protective of neurons from in vitro ischemia.
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including stroke, their early activation may cause worsening 
of ischemic injury. In fact, several studies suggest that under 
some settings, microglia tend to worsen neuronal damage 
(Flavin et al., 1997; Flavin & Ho, 1999; Flavin & Zhao, 2001; 
Flavin et al., 2000; Siao et al., 2003).  In order to explore 
the possibility that microglia may be an important early 
therapeutic target, we use a cell culture model of ischemia-
like injury to understand the contribution of microglia to 
such injury, and whether inhibiting its activation may be 
therapeutic.
Microglia  generate a variety of toxic substances which 
may exacerbate ischemic cell death (Wang et al., 2007). We 
previously showed that microglia potentiate injury to co-
cultures of astrocytes and endothelial cells subjected to 
ischemia-like insults  (Yenari et al., 2006; Zheng et al., 2008).   
Minocycline, a tetracycline family antibiotic, is recognized 
to have anti-inflammatory properties, and as such is known 
to protect against brain ischemia through this mechanism 
(Yrjänheikki et al., 1998; Yrjänheikki et al., 1999; Tang et al., 
2007).  We previously showed that minocycline, by preventing 
Introduction
Stroke is a leading cause of death and disability in many 
industrial nations, yet treatments are few and often restricted 
to few of its victims. Research into identifying important 
therapeutic targets has led to the realization that the 
inflammatory reaction accompanying acute stroke appears 
to play a largely detrimental role in stroke outcome (Wang 
et al., 2007). Thus, the identification of appropriate anti-
inflammatory treatments and understanding their mechanism 
would be of translational importance. Microglia are the brain’s 
resident immune cell, and are thought to be immune cells 
of myeloid origin. While they play important roles in brain 
development and recovery from various neurological injuries Anat Cell Biol 43:325~331, 2010 Wendy C. Huang, et al 326
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microglial activation, could prevent potentiation of ischemia-
like injury to astrocytes and endothelial cells (Yenari et al., 
2006). Here, we explore the extent to which microglia may be 
involved in potentiating neuronal death in an in vitro model 
of ischemia-like injury, and whether anti-inflammatory 
treatments only protect in the presence of added microglia, or 
whether direct effects on neurons can be demonstrated.
Materials and Methods
Cell culture & ischemia-like injury
After obtaining approval from institutional committees 
on laboratory animal use and care, primary neuron (N) and 
microglial cultures (M) were prepared from Swiss Webster 
mice using methods previously described (Dugan et al., 1995; 
Yenari & Giffard, 2001). All experiments were carried out 
in accordance with the NIH Guide for the Care and Use of 
Laboratory animals (NIH Pub. 80-23). Measures were taken 
to minimize pain and discomfort. Both N and M cultures 
contain <5% astrocytes based on immunolabeling with GFAP. 
Cocultures of neurons and microglia (NM) were prepared 
by seeding 2×10
5 microglia/ml (M) onto neuron cultures 
(N), and allowing the cocultures to stabilize 24 h prior to 
use in experiments (Fig. 1).  The cultures (N, M, and NM) 
were treated with minocycline (2 µM) to inhibit microglial 
activation or vehicle. Alternatively, cultures were treated 
with aminoguanidine (200 μM, Sigma, St. Louis, MO) to 
inhibit inducible nitric oxide synthase (iNOS), GM6001 (20 
μM, Chemicon, Temecula, CA) a broad spectrum matrix 
metalloprotease (MMP) inhibitor, a TNF-alpha blocking 
antibody (1 μg/ml, #AF-410-NA, R&D Systems, Minneapolis, 
MN) or plasminogen activator inhibitor-1 (PAI-1, 1 μg/ml, 
American Diagnostica Inc., Stamford. CT) an endogenous 
inhibitor of tissue plasminogen activator (tPA). The doses 
of reagents used were based on prior literature reports and 
manufacturer’s suggestions.
Cell cultures were subjected to ischemia-like injury 
through oxygen and glucose deprivation (OGD) for 90 min 
by placing cultures in an anaerobic chamber (O2<0.2%, Coy 
Laboratories, East Lansing, MI) in a glucose-free balanced 
salt solution (BSS0).  After 90 min of OGD, cultures were 
“reperfused” by adding 5.5 mM glucose to the media at 
normoxia.  Control cultures (no injury) were incubated with 
balanced salt solution containing 5.5 mM glucose (BSS5.5).   
Inhibitors were added to the final BSS0 wash after the cells 
were put in the anaerobic chamber.
Cultures were also treated with lipopolysaccharide (LPS, 
E. Coli serotype 055:b5, Sigma) as previously described by 
us (Yenari & Giffard, 2001). (LPS, E. Coli serotype 055:B5; 
Sigma). A concentration of 10 μg/ml was applied by diluting 
in serum-free media. This concentration was chosen as it 
was an intermediate concentration studied by our group, and 
not found to cause toxicity to primary microglia. It also led 
to consistent activation as manifested by transformation into 
amoeboid morphology and secretion of nitric oxide(Yenari 
& Giffard, 2001; Han et al., 2002). Cultures were washed 
three times in LPS containing media, then returned to the 
incubator.
Assessment of cell death
Cell death was assessed by trypan blue staining. Cells 
with neuronal morphology were identified and counted in a 
blinded fashion. Ten random high power fields were selected, 
and total cell counts and counts of trypan blue positive (dead) 
cells were made. Cells were only counted if they exhibited 
typical neuronal morphology (large, rounded cell bodies with 
long processes, which distinguish them from astrocytes and 
microglia (Ying et al., 1999)).
A second biochemical assay was also used, based on release 
of lactate dehydrogenase (LDH) released in to the media, and 
expressed as a percent of the total LDH releast after freeze-
thaw (=100%) (Lee et al., 2001).
Fig. 1. Representative neuron-microglia (NM) coculture. Neurons 
were plated at a density of 10
6 cells/ml, microglia were plated on top 
of neurons at a density of 2×10
5 cells/ml. Fluoroscent immunostains 
identify neurons (MAP-2, red, arrowheads) and microglia (IB4, green, 
arrows). Scale bar = 25 μm.Minocycline in ischemic neuron death
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Experiments were performed in triplicate from 3 separate 
dissections.
Assays
Nitric oxide (NO) levels in culture media was estimated 
using the Griess reagent (Sigma) using previously published 
methods (Han et al., 2002), and TNF-α levels were measured 
by ELISA (OptEIA, BD Biosciences, San Jose, CA) following 
kit instructions.
Immunostaining was performed in cells following fixation 
in acetone precooled to －20C for 10 minutes at 4C, then 
rinsed in PBS, and blocked in normal serum. Primary 
antibody against MAP-2 (1 : 200, Sigma) to identify neurons 
was applied followed by a Texas-red labeled secondary 
antibody (1 : 200, Jackson Labs). Between steps, sections were 
washed 3 times in PBS. Microglia were identified by staining 
with FITC-labeled Griffonia simplicifolia isolectin B4 (IB4, 10 
μg/ml, Sigma) (Han et al., 2002).
Results
Immunostaining of neuron-microglia co-cultures is shown 
in Fig. 1. Neurons are identified by MAP-2 staining in red, 
as angulated cells with long slender processes. Microglia, 
shown in green by isolectin B4 (IB4), appear to have compact 
cell bodies with shorter processes (resting form), and no 
processes with larger, rounded cell bodies in the activated 
form. Microglia were added to neuronal cultures for OGD 
experiments on NM co-cultures. Microglia increased the 
extent of cell death to a small extent compared to neurons 
alone (Fig. 2A). Thus, microglia appear to be somewhat toxic 
to neurons following OGD.
Treatment of NM cocultures with minocycline at the time 
of OGD led to a marked reduction in cell death, even beyond 
that due to the addition of microglia (Fig. 2A). Similarly, 
applying inhibitors of several inflammatory mediators led 
to similar amounts of protection. Interestingly, the extent of 
neuroprotection due to minocycline as well as all the other 
Fig. 2. (A) The addition of microglia to neuron cultures (NM-BSS0) somewhat 
increased the extent of cell death due to OGD compared to neurons alone 
(N-BSS0). However, neuroprotection was markedly enhanced by treatment of 
cocultures with minocycline (NM-mino) as well as inhibitors of iNOS (amino-
guanidine, NM-AG), MMPs (GM6001, NM-GM), and tPA (NM-PAI-1). 
(*P<0.05 vs. NM, 
†P<0.05 vs. N) (B) Treatment of neurons cultured alone 
markedly reduced OGD-induced injury (*P<0.05 vs. BSS0). BSS0 = balanced 
salt solution lacking glucose, used as a control, and also used in all washes 
with treatment, N = neurons, M = microglia (C). TNF-α inhibition protects 
neurons from OGD. Treatment of neuron cultures with a blocking antibody 
against TNF-α reduced neuron cell death as assessed by the LDH release assay. 
The extent of cell death reduction by the  blocking antibody was comparable to 
that seen by minocycline treatment. (*P<0.01 vs. no injury; 
†P<0.01 vs. OGD; 
No inj = no injury control, OGD = oxygen glucose deprivation, TNF Ab = 
TNF-α blocking antibody, mino = minocycline).Anat Cell Biol 43:325~331, 2010 Wendy C. Huang, et al 328
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inhibitors tested was greater than that due to microglia-
induced toxicity, suggesting that these treatments might have 
a direct effect on neurons. This would suggest that while 
microglia may be responsible for some increased neuron 
death, neurons themselves may produce similar inflammatory 
factors that could lead to their own death. Next, we treated 
relatively pure neuronal cultures with minocycline or the 
above inhibitors.  In all cases, treatment reduced OGD-
induced injury in neuronal cultures suggesting that inhibiting 
factors traditionally thought to emanate from immune cells 
can directly protect neurons without added microglia (Fig. 
2B). Similar observations were made when neuron cultures 
were treated with a blocking antibody against TNF-alpha (Fig 
2C).
To establish that minocycline has anti-inflammatory 
effects in our hands, primary microglia or BV2 cells (a cell 
line of transformed murine microglia (Blasi et al., 1990)) 
were subjected to 24 h OGD followed by 2 h reperfusion 
or stimulation with lipopolysaccharide (1~10 μg/ml LPS, 
Escherichia coli serotype 055:B5; Sigma, St. Louis, MO) 
for 24 h.  TNF-α and NO levels were measured in culture 
supernatants. Both LPS and OGD increased TNF-α levels 
in primary microglia, and this was markedly inhibited by 
minocycline (Figs. 3A and B). In contrast, LPS, but not OGD 
increased NO production, and this was not inhibited by 
minocycline in BV2 cells (Fig. 3C) or primary microglia (Fig. 
3D).
To determine whether neurons generate inflammatory 
mediators, and whether these could be inhibited by 
minocycline, we measured levels of TNF-α and NO in the 
media of neuron cultures subjected to OGD. Interestingly, 
neurons alone generated low levels of TNF-α and NO, 
Fig. 3. Minocycline prevented generation of TNF-α in primary microglia stimulated by LPS (A) or subjected to OGD (B). Microglia were 
stimulated by 10 μg/ml LPS for 24 h or subjected to 24 h OGD followed by 2 h reperfusion (a paradigm previously shown to cause some microglial 
death and activation (Yenari & Giffard, 2001)). TNF-α levels were measured in culture supernatants collected at the end of the experiments. In 
contrast, minocycline did not suppress NO generation, as estimated by the amount of nitrates and nitrated proteins in culture supernatants, in the 
BV2 microglial cell line (C) or primary microglia (D). Only LPS led to increased NO production, but this was not decreased by minocycline in a 
concentration found to be neuroprotective. (*P<0.001).Minocycline in ischemic neuron death
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but only NO was increased by OGD and suppressed by 
minocycline (Fig. 4).
Discussion
Microglia somewhat worsened injury to neurons in 
vitro, and this increased injury was more than blocked by 
minocycline, an inhibitor of microglia activation (Tikka & 
Koistinaho, 2001).  While these observations are in line with 
prior reports, as well as recent publications from our labs 
showing that minocycline is both anti-inflammatory and 
neuroprotective using in vivo models (Yrjänheikki et al., 1999; 
Yenari et al., 2006; Tang et al., 2007), it raised the question 
of whether minocycline has direct effects on neurons. By 
taking advantage of in vitro models where mechanisms can 
be studied more precisely, we now show direct protection of 
neurons alone by minocycline as well as by inhibiting other 
inflammatory mediators including iNOS, MMPs, TNF-
alpha and tPA. This suggests that neurons themselves may be 
capable of secreting inflammatory mediators largely thought 
to come from traditional immune cells including microglia, 
or other glial cells such as astrocytes. In fact, prior reports 
have documented expression of inflammatory cytokines 
such as TNF-α in ischemic neurons (Liu et al., 1994) and 
tPA (Siao et al., 2003), and generation of neuronal tPA has 
been thought to mediate microglial activation. Protection of 
neurons alone by the endogenous tPA inhibitor PAI-1 would 
suggest that neurons are capable of generating substances 
that are toxic to themselves. Similar conclusions could be 
made of neuronal generation of iNOS and MMPs. We have 
previously documented neuronal expression of MMPs (Lee 
et al., 2001), and a few reports indicate that some neurons 
can express iNOS after brain ischemia (Corsani et al., 2008). 
TNF-α has shown conflicting reports in the literature in terms 
of protection versus potentiation of ischemic cell death (Stoll 
et al., 2002), but our data here support a damaging effect, as 
blocking TNF-α clearly reduced neuron cell death following 
OGD.
Minocycline also exhibited differential inhibition of 
immune mediators TNF-α and NO which was cell-type and 
stimulus dependent. While minocycline remarkably inhibited 
TNF-α secretion in microglia, it did not affect TNF-α 
secretion in neurons. In contrast, LPS stimulation increased 
NO generation by microglia, but OGD did not. Minocycline 
also did not suppress OGD-induced NO generation in 
microglia, but decreased NO in neurons. Thus, OGD 
increased TNF-α in microglia, and NO in neurons, while 
minocycline suppressed these mediators in the respective 
cell types, and would suggest a complex interplay of immune 
mediators that cannot be generalized to all cell types.
Some comment on the specificity of minocycline is 
appropriate here. Originally thought to have anti-microglial 
properties, beyond its antibiotic activity, minocycline is 
also known to have anti-apoptotic effects (Zhu et al., 2002; 
Wang et al., 2003).  Tetracycline antibiotics may exert anti-
inflammatory effects by multiple mechanisms including 
inhibiting transcription of the p38 MAPK (Tikka & Kois-
tinaho, 2001) and by cross linking adhesion molecules on 
the surface of cells (Clark et al., 1994). Regardless, we suggest 
Fig. 4. Neurons increase NO generation after OGD, but not TNF-α. Neuron cultures were exposed to 90 min OGD followed by 24 h reperfusion. 
(A) Neurons secreted low levels of TNF-α, but this was not changed by OGD or minocycline treatment. (B) Low levels of nitrates and nitrated 
protein indicating NO generation were detected in culture supernatants. OGD caused NO increases which were decreased by minocycline 
treatment (*P<0.05, mino = 2 μM minocycline).Anat Cell Biol 43:325~331, 2010 Wendy C. Huang, et al 330
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that our observations argue that further studies for a better 
understanding of the complexities of immune responses 
of all cell types in the brain following injury are needed. 
Understanding inflammatory interactions of all brain cell 
types is needed to identify how they may be manipulated 
to provide neuroprotection. Studies of minocycline effects 
on brain cells in addition to microglia are timely, as 
minocycline is being studied at the clinical level for various 
neurodegenerative disorders (Blum et al., 2004; Gordon et al., 
2007) and a pilot study suggested efficacy in stroke patients 
(Lampl et al., 2007).
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